Explore By Subject Area   

Lead Editorial

T Cell Engagers, Moving Beyond Pembrolizumab, and Medicine Development for Future Patients, with Roche's Ashley Lakner

T Cell Engagers, Moving Beyond Pembrolizumab, and Medicine Development for Future Patients, with Roche's Ashley Lakner

Ashley Lakner, PhD, Head, Oncology Discovery - pRED Oncology, Roche, discusses the modalities they’re most interested in, their work moving beyond established checkpoint inhibitors and understanding immunogenicity, and the challenges in designing drugs for the patient of the future, amongst other topics.

Read More

More Related Content

Editorial

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.